Endocyte Cash Flow - Annual (NASDAQ:ECYT)

Add to My Stocks
$17.63 $0.09 (0.51%) ECYT stock closing price Sep 20, 2018 (Closing)

The Endocyte cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Endocyte profits, the balance sheet shows Endocyte debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Endocyte had cash and cash equivalents of $31.22M at beginning of the year and $18.55M at year end for 2017. Endocyte cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Endocyte has a negative cash and cash equivalents change of $-12.66M.

View details of Endocyte cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-1.31M2.19M2.47M1.92M1.31M----
Net Increase (Decrease) in Assets Liabilities-0.17M-1.4M-0.12M-58.16M-41.02M101.06M2.71M-1.51M--
Cash From (used in) Discontinued Operations----------
Other Adjustments Net20.81M9.32M6.98M8.03M6.06M4.09M2.62M---
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.06M-0.71M-0.34M-1.49M-0.82M-1.86M-0.23M-0.2M--
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments28.2M50.83M1.83M-67.06M70.12M-101.53M-67.07M15.21M--
Other Cash Inflow (Outflow) from Investment Activities-12.77M---------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares5.62M--103.49M--145.49M---
Issuance (Repayment) of Debt Securities------13.54M-13.86M--
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities--------0.1M--
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----0.03M-0.01M--0.01M---
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year31.22M15.43M45.53M52.84M33.99M61.35M16.87M8.69M--
Cash & Equivalents at Year End18.55M31.22M15.43M45.53M52.84M33.99M61.35M16.87M--
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Endocyte stock price history provides insight into historical stock price fluctuations, and Endocyte stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Endocyte has cash of $18.55M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Endocyte stock price.
  • Cash Flow from operating activities: Endocyte reported a negative operating cash flow of $-33.65M for 2017 and has seen an increase from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: Endocyte generated $15.36M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Endocyte earned $5.62M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Endocyte Cash Flow